Previous Close | 8.520 |
Open | 8.510 |
Bid | 8.450 x 0 |
Ask | 8.460 x 0 |
Day's Range | 8.290 - 8.590 |
52 Week Range | 6.950 - 11.900 |
Volume | |
Avg. Volume | 38,211,410 |
Market Cap | 100.955B |
Beta (5Y Monthly) | 0.68 |
PE Ratio (TTM) | 15.67 |
EPS (TTM) | 0.540 |
Earnings Date | Aug 24, 2022 - Aug 29, 2022 |
Forward Dividend & Yield | 0.18 (2.11%) |
Ex-Dividend Date | May 31, 2022 |
1y Target Est | 12.16 |
Subscribe to Yahoo Finance Plus to view Fair Value for 1093.HK
Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision oncology products for patients with genomically defined cancers, today announced that it has entered into an exclusive license agreement with CSPC Megalith Biopharmaceutical Co., Ltd, a subsidiary of CSPC Pharmaceutical Group Limited (CSPC; HKEX: 01093) to develop and commercialize EO-3021 (SYSA1801), a differentiated, clinical stage antibody drug conjugate (ADC) targeting